ImmunityBio Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ImmunityBio, Inc. (IBRX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-413.65-583.20-417.32-349.85-221.85
Depreciation & Amortization17.5518.5141.7919.5912.74
Deferred Income Tax0.000.000.00-0.010.00
Stock Based Compensation34.4349.1640.1857.182.19
Change in Working Capital-19.423.98-2.46-4.7616.36
Change in Accounts Receivable-2.360.000.000.000.00
Change in Inventory-8.270.000.000.000.00
Change in Accounts Payable-3.17-6.488.00-3.722.57
Change in Other Working Capital-5.6210.45-16.0018.1013.79
Other Operating Activities-10.16100.0540.4860.618.86
Net Cash from Operating Activities-391.24-366.76-337.51-274.42-171.72
Investing Activities
Capital Expenditures-6.89-30.5899.3933.56-1.67
Acquisitions-1.000.00-1.000.000.00
Purchases of Investments-140.220.11126.69-141.75-18.14
Sales/Maturities of Investments136.6110.47127.69-71.820.00
Other Investing Activities-0.750.000.000.000.00
Net Cash from Investing Activities-12.25-30.4727.30-84.89-19.81
Financing Activities
Debt Repayment96.89-0.08-0.060.000.00
Common Stock Issued111.36110.4060.43164.5387.48
Common Stock Repurchased0.00-3.44-0.62-4.06-0.50
Other Financing Activities73.38192.76-0.96-3.050.00
Net Cash from Financing Activities281.63558.34233.61505.44150.68
Summary
Effect of Forex Changes on Cash-0.02-0.290.280.050.00
Net Change in Cash-121.88160.82-76.60146.14-40.89
Cash at Beginning of Period265.79104.97181.2835.090.00
Cash at End of Period143.91265.79104.64181.100.00
Free Cash Flow-398.12-397.34-436.90-287.48-173.39
Supplemental Disclosures
Interest Paid92.3277.1935.442.110.04
Income Taxes Paid0.020.010.000.010.01